Albany Molecular Research, Inc. ("Albany Molecular" or the Company) is an American contract research and manufacturing organization for the pharmaceutical and biotechnology industries.

According to the law firm press release, the lawsuit alleges that Albany Molecular issued materially false and misleading statements about its business and financial prospects. On August 5, 2014, Albany Molecular announced its second quarter 2014 results and increased its 2014 adjusted EPS guidance to $0.87 - $0.92 to reflect the addition of OsoBio and the strengthening of its contract business. On November 5, 2014, the Company reported a loss of $8.6 million in its third quarter and lowered its 2014 adjusted EPS guidance to $0.67 and $0.73. The Company disclosed that a business interruption event at its OsoBio facility in late July, prior to its increased EPS estimates in August, contributed to a weak third quarter and the facility will not be back online until mid-November. On this news, shares of Albany Molecular Research fell sharply during intraday trading on November 5, 2014, damaging investors.

On January 26, 2015, the Court issued an Order appointing lead Plaintiffs and approving lead Counsel. Lead Plaintiffs filed an amended Complaint on March 31.

The parties entered into a Stipulation of Settlement on February 9, 2017. The Settlement was preliminarily approved on June 26. On October 13, the Court approved Attorneys' Fees and Expenses and filed an Order of Dismissal with Prejudice.